ArticleThe oncologist2014
Barriers and challenges to global clinical cancer research.
Article in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Barriers for conducting clinical trials in developing countries- a systematic review.International journal for equity in health · 2018Pooled it
- Training Needs Assessment and Capacity Building of Clinical Trial Assessors and Ethical Reviewers to Strengthen Regulatory Review in Tanzania.Therapeutic innovation & regulatory science · 2026Article
- A comprehensive analysis and visualization of immune-related adverse events in lung cancer immunotherapy a bibliometric study.Discover oncology · 2026Review
- Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.Contemporary clinical trials communications · 2026Article
- The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024).Cancers · 2025Article
- Barriers and Opportunities for Cancer Clinical Trials in Low- and Middle-Income Countries.JAMA network open · 2025Article
- Oncology Early-Phase Clinical Trials in the Middle East and North Africa: A Review of the Current Status, Challenges, Opportunities, and Future Directions.Journal of immunotherapy and precision oncology · 2024Review
- Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)-a white paper.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Review
- Historical evolution of cancer genomics research in Latin America: a comprehensive visual and bibliometric analysis until 2023.Frontiers in genetics · 2024Article
- Randomised clinical trials in surgery: are we at a crossroads?Annals of medicine and surgery (2012) · 2024Article
- Disparities in COVID-19 clinical studies from high-income and low-and middle-income countries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Radiation Oncology Research in Asia: Current Status and a Peep Into the Future From the Federation of Asian Organizations for Radiation Oncology.JCO global oncology · 2023Article
- Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial.JCO global oncology · 2023Article
- Review
- Promoting patient engagement in cancer genomics research programs: An environmental scan.Frontiers in genetics · 2023Article
- Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop.JCO global oncology · 2022Article
- The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research.The Lancet. Oncology · 2021Review
- Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.Trials · 2021Article
- An investigation into the factors affecting investigator-initiated trial start-up in Ireland.Trials · 2020Article
- Knowledge and Attitude of Medical Residents Towards Cancer Clinical Trials in Jordan.International journal of general medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 12 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research.
methodsThe American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Web-based survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles.
resultsEighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) at academic hospitals (90%). Researchers from HICs were more involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lack of time or competing priorities and procedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively.
conclusionLack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.